BMS receives US FDA approval for Camzyos to treat cardiomyopathy
The approval is based on findings from Phase III EXPLORER-HCM clinical trial that enrolled 251 adults with obstructive HCM.

The approval is based on findings from Phase III EXPLORER-HCM clinical trial that enrolled 251 adults with obstructive HCM.
The antibodies showed potential for treating individuals who are at high-risk for atherosclerotic cardiovascular disease.
The additional clinical benefits empagliflozin offers will strengthen its position in an increasingly competitive SGLT-2I class.
ByMavacamten is a selective cardiac myosin inhibitor currently in pre-registration for hypertrophic cardiomyopathy (HCM) in the US.
ByThe EC approval is based on results from the Phase III EMPEROR-Preserved trial of 10mg empagliflozin versus placebo.
The approval is based on results from the Phase III EMPEROR-Preserved clinical trial of a once-daily dose of 10mg empagliflozin.
Abbisko is eligible to receive up to $258m in milestone payments from Lilly.
The companies collaborated initially in 2019 to use AI and machine learning to develop new therapies for CKD and IPF.